tiprankstipranks
Trending News
More News >
BioNTech SE (BNTX)
NASDAQ:BNTX
US Market

BioNTech SE (BNTX) Stock Forecast & Price Target

Compare
4,579 Followers
See the Price Targets and Ratings of:

BNTX Analyst Ratings

Moderate Buy
19Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
Based on 19 analysts giving stock ratings to
BioNTech
SE
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$140.00
▲(27.10%Upside)
Based on 19 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $140.00 with a high forecast of $181.00 and a low forecast of $110.00. The average price target represents a 27.10% change from the last price of $110.15.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","182":"$182","103.25":"$103.3","129.5":"$129.5","155.75":"$155.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":181,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$181.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$110.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,103.25,129.5,155.75,182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,118.32307692307691,123.54615384615384,128.76923076923077,133.9923076923077,139.2153846153846,144.43846153846152,149.66153846153844,154.8846153846154,160.1076923076923,165.33076923076922,170.55384615384617,175.77692307692308,{"y":181,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,115.16923076923077,117.23846153846154,119.3076923076923,121.37692307692308,123.44615384615385,125.51538461538462,127.58461538461538,129.65384615384616,131.72307692307692,133.7923076923077,135.86153846153846,137.93076923076924,{"y":140,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,112.86153846153846,112.62307692307692,112.38461538461539,112.14615384615384,111.9076923076923,111.66923076923077,111.43076923076923,111.1923076923077,110.95384615384616,110.71538461538461,110.47692307692307,110.23846153846154,{"y":110,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.6,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$181.00Average Price Target$140.00Lowest Price Target$110.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BNTX
TipRanks AITipRanks
Not Ranked
TipRanks
$119
Hold
8.03%
Upside
Reiterated
06/03/25
BioNTech's strong balance sheet and positive technical momentum are offset by profitability challenges and financial losses highlighted in the earnings call. Strategic investments in oncology could drive future growth, but current financial risks weigh on the overall score.
H.C. Wainwright Analyst forecast on BNTX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$134$145
Buy
31.64%
Upside
Reiterated
06/05/25
Strategic Partnership and Financial Stability Drive Buy Rating for BioNTech
Deutsche Bank  Analyst forecast on BNTX
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
$140
Buy
27.10%
Upside
Reiterated
06/03/25
Analysts Conflicted on These Healthcare Names: Neuren Pharmaceuticals Limited (Other OTC: NURPF), GlaxoSmithKline (NYSE: GSK) and BioNTech SE (NASDAQ: BNTX)
Berenberg Bank Analyst forecast on BNTX
Harry GillisBerenberg Bank
Berenberg Bank
$130$150
Buy
36.18%
Upside
Reiterated
06/03/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Canaccord Genuity Analyst forecast on BNTX
John NewmanCanaccord Genuity
Canaccord Genuity
$171
Buy
55.24%
Upside
Reiterated
06/03/25
Promising Efficacy and Safety of BioNTech's BNT324 Supports Buy Rating
Truist Financial Analyst forecast on BNTX
Asthika GoonewardeneTruist Financial
Truist Financial
$151$155
Buy
40.72%
Upside
Reiterated
06/03/25
BioNTech SE's Strategic Partnership with Bristol Myers Squibb Boosts Financial Prospects and Reinforces Buy Rating
Clear Street Analyst forecast on BNTX
William MaughanClear Street
Clear Street
$155$181
Buy
64.32%
Upside
Reiterated
06/02/25
Clear Street Remains a Buy on BioNTech SE (BNTX)
Oppenheimer Analyst forecast on BNTX
Hartaj SinghOppenheimer
Oppenheimer
Hold
Reiterated
06/02/25
Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)
Wells Fargo Analyst forecast on BNTX
Mohit BansalWells Fargo
Wells Fargo
$200$170
Buy
54.33%
Upside
Reiterated
06/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
Jefferies Analyst forecast on BNTX
Akash TewariJefferies
Jefferies
$149$151
Buy
37.09%
Upside
Reiterated
06/02/25
Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)
Citi
$140
Buy
27.10%
Upside
Reiterated
06/02/25
BioNTech SE (BNTX) Gets a Buy from Citi
UBS
$115
Hold
4.40%
Upside
Reiterated
06/02/25
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
Leerink Partners Analyst forecast on BNTX
Daina GrayboschLeerink Partners
Leerink Partners
$112$115
Buy
4.40%
Upside
Reiterated
06/02/25
Strategic Partnership with BMY Boosts BioNTech's Oncology Prospects and Financial Stability
J.P. Morgan Analyst forecast on BNTX
Jessica FyeJ.P. Morgan
J.P. Morgan
Hold
Reiterated
06/01/25
BioNTech SE: Hold Rating Amid Mixed Clinical Trial Results for BNT327
Goldman Sachs Analyst forecast on BNTX
Asad HaiderGoldman Sachs
Goldman Sachs
$110
Hold
-0.14%
Downside
Initiated
05/29/25
BioNTech SE: Hold Rating Amid Market Challenges and Promising Oncology Prospects
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BNTX
TipRanks AITipRanks
Not Ranked
TipRanks
$119
Hold
8.03%
Upside
Reiterated
06/03/25
BioNTech's strong balance sheet and positive technical momentum are offset by profitability challenges and financial losses highlighted in the earnings call. Strategic investments in oncology could drive future growth, but current financial risks weigh on the overall score.
H.C. Wainwright Analyst forecast on BNTX
Robert BurnsH.C. Wainwright
H.C. Wainwright
$134$145
Buy
31.64%
Upside
Reiterated
06/05/25
Strategic Partnership and Financial Stability Drive Buy Rating for BioNTech
Deutsche Bank  Analyst forecast on BNTX
Emmanuel PapadakisDeutsche Bank
Deutsche Bank
$140
Buy
27.10%
Upside
Reiterated
06/03/25
Analysts Conflicted on These Healthcare Names: Neuren Pharmaceuticals Limited (Other OTC: NURPF), GlaxoSmithKline (NYSE: GSK) and BioNTech SE (NASDAQ: BNTX)
Berenberg Bank Analyst forecast on BNTX
Harry GillisBerenberg Bank
Berenberg Bank
$130$150
Buy
36.18%
Upside
Reiterated
06/03/25
Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)
Canaccord Genuity Analyst forecast on BNTX
John NewmanCanaccord Genuity
Canaccord Genuity
$171
Buy
55.24%
Upside
Reiterated
06/03/25
Promising Efficacy and Safety of BioNTech's BNT324 Supports Buy Rating
Truist Financial Analyst forecast on BNTX
Asthika GoonewardeneTruist Financial
Truist Financial
$151$155
Buy
40.72%
Upside
Reiterated
06/03/25
BioNTech SE's Strategic Partnership with Bristol Myers Squibb Boosts Financial Prospects and Reinforces Buy Rating
Clear Street Analyst forecast on BNTX
William MaughanClear Street
Clear Street
$155$181
Buy
64.32%
Upside
Reiterated
06/02/25
Clear Street Remains a Buy on BioNTech SE (BNTX)
Oppenheimer Analyst forecast on BNTX
Hartaj SinghOppenheimer
Oppenheimer
Hold
Reiterated
06/02/25
Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)
Wells Fargo Analyst forecast on BNTX
Mohit BansalWells Fargo
Wells Fargo
$200$170
Buy
54.33%
Upside
Reiterated
06/02/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
Jefferies Analyst forecast on BNTX
Akash TewariJefferies
Jefferies
$149$151
Buy
37.09%
Upside
Reiterated
06/02/25
Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)
Citi
$140
Buy
27.10%
Upside
Reiterated
06/02/25
BioNTech SE (BNTX) Gets a Buy from Citi
UBS
$115
Hold
4.40%
Upside
Reiterated
06/02/25
UBS Keeps Their Hold Rating on BioNTech SE (BNTX)
Leerink Partners Analyst forecast on BNTX
Daina GrayboschLeerink Partners
Leerink Partners
$112$115
Buy
4.40%
Upside
Reiterated
06/02/25
Strategic Partnership with BMY Boosts BioNTech's Oncology Prospects and Financial Stability
J.P. Morgan Analyst forecast on BNTX
Jessica FyeJ.P. Morgan
J.P. Morgan
Hold
Reiterated
06/01/25
BioNTech SE: Hold Rating Amid Mixed Clinical Trial Results for BNT327
Goldman Sachs Analyst forecast on BNTX
Asad HaiderGoldman Sachs
Goldman Sachs
$110
Hold
-0.14%
Downside
Initiated
05/29/25
BioNTech SE: Hold Rating Amid Market Challenges and Promising Oncology Prospects
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month
xxx
Success Rate
15/27 ratings generated profit
56%
Average Return
+2.16%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +2.16% per trade.
3 Months
xxx
Success Rate
11/24 ratings generated profit
46%
Average Return
+4.42%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.83% of your transactions generating a profit, with an average return of +4.42% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
16/23 ratings generated profit
70%
Average Return
+20.59%
reiterated a buy rating 25 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +20.59% per trade.
2 Years
xxx
Success Rate
18/23 ratings generated profit
78%
Average Return
+34.33%
reiterated a xxx
rating 25 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 78.26% of your transactions generating a profit, with an average return of +34.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
0
6
8
11
7
Buy
27
34
35
46
37
Hold
4
4
4
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
44
47
66
52
In the current month, BNTX has received 44 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 140.00.
Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$2.41 with a range of -$3.80 to $3.25. The previous quarter’s EPS was -$1.98. BNTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.
Next quarter’s earnings estimate for BNTX is -$2.41 with a range of -$3.80 to $3.25. The previous quarter’s EPS was -$1.98. BNTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $172.61M with a range of $94.01M to $464.44M. The previous quarter’s sales results were $192.39M. BNTX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.
Next quarter’s sales forecast for BNTX is $172.61M with a range of $94.01M to $464.44M. The previous quarter’s sales results were $192.39M. BNTX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 140.00.
    What is BNTX’s upside potential, based on the analysts’ average price target?
    BioNTech SE has 27.10% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BNTX a Buy, Sell or Hold?
          BioNTech SE has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
            What is BioNTech SE’s price target?
            The average price target for BioNTech SE is 140.00. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $181.00 ,the lowest forecast is $110.00. The average price target represents 27.10% Increase from the current price of $110.15.
              What do analysts say about BioNTech SE?
              BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
                How can I buy shares of BNTX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis